Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
Thomas DesRosier, Chief Legal Officer and Executive Vice President at Seres Therapeutics, Inc. (NASDAQ:MCRB), recently executed a stock transaction that might catch the attention of investors. According to the latest SEC filing, DesRosier sold 4,300 shares of common stock on February 18, 2025, at prices ranging from $0.81 to $0.8385 per share, totaling approximately $3,485. The transaction comes as the company’s stock trades near $0.83, down about 20% over the past year, according to InvestingPro data.
The sale was part of a pre-established trading plan under Rule 10b5-1, primarily aimed at covering taxes related to the vesting of restricted stock units. Prior to this sale, DesRosier had exercised options to acquire a total of 11,564 shares of common stock on February 15, 2025, through the conversion of restricted stock units. These transactions were executed without any cash exchange, as the restricted stock units were settled at no cost. With the company’s next earnings report due on March 11, InvestingPro subscribers can access detailed insider trading patterns and 8 additional key insights about MCRB’s financial health.
Following these transactions, DesRosier holds a total of 142,456 shares of Seres Therapeutics common stock directly. The company, based in Cambridge, Massachusetts, operates in the pharmaceutical preparations industry and is incorporated in Delaware. Recent InvestingPro analysis indicates the company faces challenges with cash burn and profitability, with an EBITDA of -$36.4 million in the last twelve months.
In other recent news, Seres Therapeutics reported receiving a $50 million installment from Nestlé Health Science as part of the transition obligations following the sale of its VOWST business. This financial influx, alongside an anticipated $25 million installment in July 2025, is expected to support Seres’ operations into early 2026. Additionally, the FDA has granted Breakthrough Therapy designation to Seres’ investigational drug SER-155, aimed at reducing bloodstream infections in patients undergoing allo-HSCT. This designation is anticipated to provide more intensive FDA guidance and potentially expedite the review process. Seres released data showing SER-155 achieved a 77% reduction in relative risk of bacterial bloodstream infections compared to a placebo in a Phase 1b study. In corporate developments, Seres Therapeutics has expanded its Board of Directors with the appointment of Dr. Hans-Juergen Woerle as a new Class III director. This appointment follows a rights agreement with Nestlé, which holds a significant stake in the company. These developments reflect ongoing strategic and operational advancements at Seres Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.